Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer

Abstract Therapeutic strategies which target immune checkpoint markers and enable the immune system to initiate immune responses against tumor cells represent a major advancement in cancer therapy. The response rate to anti-PD-1 checkpoint inhibition in head and neck cancer is about 20%, which under...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Patrick J. Schuler, Franziska Oliveri, Lisa Puntigam, Klara Six, Carlotta Kaißer, Julia Maier, Simon Laban, Adrian von Witzleben, Cornelia Brunner, David A. C. Messerer, Hubert Schrezenmeier, Thomas K. Hoffmann, Marlies Goetz, Jochen Greiner
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Nature Portfolio 2026-02-01
سلاسل:	Scientific Reports
الموضوعات:	Anti-LAG-3 (Lymphocyte activation gene 3) Anti-PD-1 (Programmed death-1, aPD-1) Anti-TIM-3 (T cell immunoglobulin and mucin-domain containing-3) Head and neck cancer (HNC) Immune checkpoints Melanoma-associated antigen (MAGE)
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41598-026-38740-z
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!